Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024

Rallybio Corp

2024-Q1 EPS reported -$0.47

Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.
Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.
Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.
Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.
Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rallybio Corp reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-24-000053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.